tbuckley/cabot-search huggingface dataset:
Traction device to remove an adenoma in the appendiceal orifice by endoscopic submucosal dissection
Authors: T. Takeda, T. Murakami, N. Sakamoto, S. Goto, H. Ritsuno, H. Ueyama, H. Mori, K. Matsumoto, T. Shibuya, T. Osada, A. Nagahara, T. Ogihara, S. Watanabe
Journal: Endoscopy (2013)

Adenomatous polyps of the appendix are rare [1] [2]; in some cases polypectomy is unsuccessful and surgical treatment is required [3]. Appendiceal polypectomy at colonoscopy is carried out extremely rarely [4]. This is the first reported case of an adenoma of the appendix resected using a traction device during endoscopy.
Reduction of Hospital Mortality from Acute Myocardial Infarction by Anticoagulant Therapy
Authors: Baruch Modan, Mordechai Shani, Stanley Schor, Michaela Modan
Journal: New England Journal of Medicine (1975)

A nationwide study of all 2330 patients hospitalized for a first definite acute myocardial infarction in Israel during a one-year period revealed a significantly lower 21-day mortality rate of patients treated by anticoagulants: 8.3 versus 27.3 per cent in those not receiving such therapy (p less than 0.0001). Out of the 22 hospitals studied, the effect was present in 18, absent in two, and not assessable in two. There was a highly significant inverse correlation between the proportion of patients receiving anticoagulant therapy in each hospital and the total 21-day mortality from infarction in that institution (r equals 0.57; less than 0.01). The superior survival of patients on anticoagulant therapy did not seem related to differences in age, sex, disease severity, site of infarction, diagnostic criteria or type of hospital. Despite the obvious limitations of retrospective studies the data justify a re-evaluation of the approach to the problem by further investigative effort.
La Médecine Du Coeur
Authors: Paul D. White
Journal: New England Journal of Medicine (1949)

IN 1806 there was published at Lyon in France by Mark Anthony Petit an essay entitled "La Médecine du Coeur," literally translated medicine of the heart but actually signifying not cardiology but medicine from the heart — that is, benevolence in the practice of medicine. It was composed of four parts written as poetry and presented as such before the Academy of Lyon, the first in 1800 on the difficulties and disappointments connected with the profession of medicine, the second in 1801 on trust in the physician, the third in 1802 on gratitude toward physicians, and the fourth in 1805 . . .
P654Left and right atria show different basal expression patterns of metabolic enzymes in a proteomic-based gene ontology representation study
Authors: A Dietl, I Winkel, R Deutzmann, J Hupf, G Riegger, A Luchner, C Birner
Journal: Cardiovascular Research (2014)

Background: Left and right atria show compelling differences regarding organogenesis and specific clinical diseases, as exemplarily evidenced by a different arrhythmic susceptibility. This strongly indicates a diverging basal left and right atrial molecular set-up which has not been sufficiently characterised so far. Objective: To determine basal differences between left and right atrial protein expressions indicating interatrial differential molecular pathways. Methods: Left and right atrial whole proteome lysates of seven healthy rabbits were compared by two-dimensional gel electrophoresis. Significant differentially expressed proteins were identified by tandem mass spectrometry. Significantly differing proteins were classified according to their putative biological function. A gene ontology representation study was carried out using the PANTHER database tools of a binomial statistic test including a Bonferroni correction for multiple testing. To confine this analysis to the subset of proteins which is potentially identifiable upon two dimensional gel electrophoresis, a reference list was calculated in silico based on the UniProt Knowledgebase by the ExPASy-TagIdent tool including proteins with an isoelectric point 4.5 to 8 and molecular weights 25.5-144.5kDa. Results: Echocardiography showed normal left ventricular function and atrial morphology in the seven rabbits. Upon proteomic analysis, 39 proteins displayed significant expression differences between left and right atria. 18 of them were allocated in the mitochondria. The in silico calculated reference list comprised 7748 proteins. Three biological processes of metabolism were significantly overexpressed in the left atrium: generation of precursor metabolites and energy (p=1.1*10-4), oxidative phosphorylation (p=2.5*10-3) and respiratory electron transport chain (p=0.01). Conclusion: Left and right atria show significant differential expression of 39 proteins in a whole proteome study. Going beyond individual proteins to biological processes, a gene ontology representation study showed three components of energetic catabolism significantly overexpressed in the healthy left atrium. This result is consistent with the mitochondrial allocation of nearly half of the detected differential proteins. In conclusion, our data indicate an interatrial difference of the metabolic proteome. Further studies are necessary to identify underlying physiological causes and regulatory mechanisms.
FRI0522 The part of function (health assessment questionnaire) in the sf-6d and eq-5d utility measures varies over time in early arthritis (espoir cohort): questionable validity of deriving quality adjusted life years from haq
Authors: C. Gaujoux-Viala, A.-C. Rat, K. Hosseini, R.-M. Flipo, F. Guillemin, B. Fautrel
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> There is growing emphasis on the cost-effectiveness of treating early arthritis (EA). As few studies directly record the utility measures needed for economic analyses, mapping is often used. Health Assessment Questionnaire (HAQ) is ‘converted’ into utility using regression. The use of such transformed data by regulatory bodies which determine drug availability raises concern as it involves mathematical transformation between measures which may not be clinically equivalent and with potentially variable interrelationships over time. <h3>Objectives</h3> We aimed 1) To assess characteristics associated with SF-6D and EQ-5D utility measures in EA 2) To check whether these associations are stable over 3 years. <h3>Methods</h3> - <i>Patients</i>: included in the French nationwide cohort of EA ESPOIR (at least 2 swollen joints for less than 6 months and suspicion of RA). -<i>Data available</i>: SF-6D and EQ-5D utility measures were longitudinally assessed in 813 patients with EA (at baseline, 6 months, 1, 2 and 3 years). Bio-clinical variables and X-rays were also recorded. -<i>Analysis</i>: The determinants of SF-6D and EQ-5D utility measures at each time-point were assessed by multivariate linear regressions in 618 EA patients followed over 3 years. <h3>Results</h3> At baseline, SF-6D was essentially determined by function, HAQ explaining 50.2% of the variance, whereas after 6 months, SF-6D was essentially determined by mental status (55.8 to 57.6% of the variance) and the HAQ represented only 7.3 to 13.2%. At each time-point, EQ-5D was essentially determined by function, HAQ explaining 36.9 to 44.2% of the variance, except at 1 year, it was essentially determined by mental status, explaining 40.8% of the variance and the HAQ only 11% (figure). <h3>Image/graph</h3> <h3>Conclusions</h3> The major impact of functional ability and mental status, and the variability of the utility determinants over time have consequences for the utility evaluation in EA patients. Evaluation of treatment cost-utility should not be based on utility data transformed from HAQ. <h3>Disclosure of Interest</h3> None Declared
SAT0500 Ultrasound-Guided Injections for Rheumatoid Arthritis and Spondyloarthritis: A Systematic Literature Review
Authors: M. Andrés, M. P. Rosario, E. Loza, I. Moller, E. Naredo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In recent years, ultrasound (US)-guided injections are commonly used for the management of rheumatic diseases, probably because a better outcome and safer profile is presumed due to higher anatomic accuracy. To our knowledge, it has never been critically evaluated. <h3>Objectives</h3> To assess the efficacy and safety of US-guided injections in patients with inflammatory arthritis. <h3>Methods</h3> A systematic literature search was performed in Medline, EMBASE and the Cochrane library from 1950 to May 2012, and also a hand search on references of the included studies. Search was limited to rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Only controlled intervention studies using palpation-guided injection, injection guided by other imaging techniques, or placebo as the control group, were included. The Cochrane Risk of Bias tool for intervention studies was used to assess the quality of the included studies. <h3>Results</h3> From a total of 945 identified references, only 5 papers fulfilled the inclusion criteria and were selected. All were randomised controlled trials including a total of 702 adult patients with RA [1] or mixed populations (RA and PsA [2,3] or RA and osteoarthritis [4,5]). Risk of bias was considered low to moderate. The study intervention was US-guided injections of glucocorticoid plus lidocaine versus palpation-guide injections in patients with active synovitis in all included studies. Pain was the main outcome assessed, which differing results: two studies with good quality [1,2] noted no differences between techniques, whereas three studies [3-5] showed significant pain improvement with US-guided injections, but with a moderate risk of bias. Function and stiffness were assessed in two studies [1,2], with no significant differences. Accuracy was higher overall for US-guided injections (83% vs 66%, p=0.01) in one study [2], but not in wrists (90% vs 90%, p=1.00) in other study [1]. No safety evaluation was done in included studies. No studies focused on enthesitis or tenosynovitis, or enrolling patients with SpA or JIA, were identified. <h3>Conclusions</h3> Despite the extensive use in clinical practice, superiority of US-guided injections over palpation remains controversial in patients with RA, whereas no evidence for SpA or JIA was found. Accordingly, further studies are warranted. <h3>References</h3> Luz. Ann Rheum Dis 2008; 67:1198. Cunnington. Arthritis Rheum 2010; 62:1862. Sibbitt. J Rheumatol 2011; 38:252. Sibbitt. J Rheumatol 2009; 36:1892. Sibbitt, Jr. Scand J Rheumatol 2012; 41:66. <h3>Disclosure of Interest</h3> None Declared
PREVALENCE, CLINICAL PROFILE AND SHORT-TERM PROGNOSIS OF INTERATRIAL BLOCK IN PATIENTS ADMITTED FOR WORSENING OF HEART FAILURE
Authors: Jesus Alvarez-Garcia, Albert Massó-Van Roessel, Miquel Vives-Borras, Andreu Ferrero-Gregori, Manuel Martínez-Sellés, Antonio Bayés de Luna, Juan Cinca
Journal: Journal of the American College of Cardiology (2016)
THU0177 Comparative Study on the Presence of Ultrasound Subclinical Synovitis between Patients with RA and PSA in Clinical Remission or Low Disease Activity in Treatment with Anti-TNF Therapy: Table 1.
Authors: J. Ramírez García, J. Inciarte-Mundo, V. Ruíz-Esquide, S. Cabrera, R. Celis, A. Cuervo, C. Saura, J.D. Cañete, R. Sanmartí
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To analyse clinical and sonographic differences between patients with rheumatoid arthritis and psoriatic arthritis with clinical remission or low disease activity on anti-TNF therapy. <h3>Methods</h3> Subanalysis of the 12 months follow-up prospective study INMUNOREMAR. Patients diagnosed with rheumatoid arthritis or polyarticular psoriatic arthritis in clinical remission or low disease activity by DAS28 on anti-TNF therapy (etanercept, adalimumab or infliximab) were included. Clinical, epidemiological, demographic and serological data at baseline were analysed. Ultrasound scans of both knees and hands (wrists, metacarpophalangeal [MCP], proximal interphalangeal [PIP] flexor and extensor tendons of the hand) were made. We quantified synovial hypertrophy (grades 0-3) and power Doppler signal (grades 0-3) in all patients and a global synovitis score was calculated. Data at study entry are presented. <h3>Results</h3> 100 patients (46 RA and 54 PsA, mean age (SD) 58.2 (11.4) years, disease duration 15.9 (8.8) years) were included. 50 patients were on etanercept, 35 adalimumab and 15 infliximab. 51 patients (39 PsA) were on monotherapy and 46 (31 PsA) were on anti-TNF dose-reduction. 48 patients had power Doppler signal and 45 met criteria for ultrasound-active synovitis (synovial hypertrophy + Power Doppler signal). Patients with psoriatic arthritis had significantly-less disease activity (p=0.0001 for DAS28-VSG) and fewer sonographic findings (Table 1): only 14 patients with PsA met criteria for active synovitis (31 for RA, p=0.0001). <h3>Conclusions</h3> Among patients with clinical remission or low disease activity and anti-TNF therapy, PsA patients had significantly less clinical and sonographic activity. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5519
Abstract 3294: Apoptotic effect of thymus extract plus Lactobacillus kefiri P-IF on human myeloid leukemia (HL60/AR) cancer cells.
Authors: Mamdooh H. Ghoneum, Mark Henary, Yoshikazu Seto
Journal: Cancer Research (2013)

Abstract Apoptosis involves a cascade of biochemical events that is tightly regulated. Induction of apoptosis in tumor cells is a promising approach to curing cancer. Therefore, new and safe treatment methods that maximize cancer cells apoptosis are therefore highly sought after. In this study, we examined the effect of gross thymus extract (GTE) combined with freeze dried, heat-killed Lactobacillus kefiri P-IF in the induction of apoptosis in human multidrug-resistant (MDR) myeloid leukemia (HL60/AR) cells in vitro and evaluated the mechanism underlying its effect. L. kefiri P-IF is a specific strain of lactic acid bacteria that has a unique DNA sequence and PET scans show a 99.6% homology with regular kefiris. To identify any synergistic effect of these two products, tumor cells were cultured for three days with 1) GTE at a concentration of 1.25 mg/ml or 2) L.kefiri P-IF at a concentration of 1.25 mg/ml or 3) a combination of both products at the same concentrations. The apoptotic response was assessed by propidium iodide assay and expression of Bcl2, anti-apoptotic protein, was determined by flow cytometry. Results showed that GTE and L.kefiri P-IF induced apoptosis in HL60/AR cells; GTE caused 37% apoptosis while L.kefiri P-IF caused 17% apoptosis, as compared to 7% for control cancer cells without treatment. When cancer cells were cultured in the presence of both GTE and L.kefiri P-IF, 60% apoptosis of cancer cells was detected. This data was confirmed by giemsa stained cytospin preparation. The synergistic apoptotic effect was associated with decreased expression of Bcl2. MFC: 74, 68, 61 and 50 for control untreated cells, GTE, L.kefiri P-IF and GTE + kefiri P-IF respectively. Atomic Force Microscopy studies were performed and showed clear signs of apoptotic cancer cells including membrane blebbing. These results demonstrate that GTE + L.kefiri P-IF induces apoptosis on cancer cells that exceed the effect of either agent alone, and this agent may represent a new class of adjuvants for the treatment of leukemia. GTE (Thymax) was provided by the YS Nature Company, Tokyo, Japan; L.kefiri P-IF was provided by Paitos Co., Ltd. Yokohama, Kanagawa, Japan. Citation Format: Mamdooh H. Ghoneum, Mark Henary, Yoshikazu Seto. Apoptotic effect of thymus extract plus Lactobacillus kefiri P-IF on human myeloid leukemia (HL60/AR) cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3294. doi:10.1158/1538-7445.AM2013-3294 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected Persons
Authors: David D. Ho, Tarsem Moudgil, Masud Alam
Journal: New England Journal of Medicine (1989)

We used end-point-dilution cultures to measure the level of infectious human immunodeficiency virus type 1 (HIV-1) in peripheral-blood mononuclear cells (PBMC) and plasma of 54 infected patients who were not receiving antiviral chemotherapy. HIV-1 was recovered from the plasma and PBMC of every seropositive patient, but from none of 22 seronegative control subjects. The mean titers in plasma were 30, 3500, and 3200 tissue-culture-infective doses (TCID) per milliliter for patients with asymptomatic infection, the acquired immunodeficiency syndrome (AIDS), and the AIDS-related complex, respectively. In PBMC, the mean titers were significantly higher for symptomatic patients (AIDS, 2200, and AIDS-related complex, 2700 TCID per 10(6) PBMC) than asymptomatic patients (20 TCID per 10(6) PBMC). The values for the symptomatic patients were considered to indicate that at least 1 in 400 circulating mononuclear cells harbored HIV-1. The HIV-1 titers of seven patients with AIDS or AIDS-related complex treated with zidovudine for four weeks decreased significantly in plasma but not in PBMC. In addition, the mean titer in the plasma of 20 patients receiving long-term zidovudine treatment (130 TCID per milliliter) was 25-fold lower than the mean for comparable untreated patients with AIDS or AIDS-related complex. We conclude that the levels of HIV-1 in plasma and PBMC are much higher than previous estimates. This high degree of HIV-1 viremia raises the possibility that the direct cytopathic effect of this retrovirus alone may be sufficient to explain much of the pathogenesis of AIDS.
COMPARISON OF THE PROGNOSTIC UTILITIES OF CREATININE-BASED AND CALCULATED CREATININE CLEARANCE-BASED MID-TERM RENAL INSUFFICIENCY UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Arata Hagikura, Kenji Goto, Hiroki Yamane, Kazunari Kobayashi, Yoshimasa Morimoto, Yuetsu Kikuta, Katsumasa Sato, Masahito Taniguchi, Shigeki Hiramatsu, Hideo Takebayashi, Seiichi Haruta
Journal: Journal of the American College of Cardiology (2016)
SP0022 Knock-in mice reveal in vivo consequences of MMP activity for OA
Authors: A. Fosang
Journal: Annals of the Rheumatic Diseases (2013)

We have compared knockin mice with aggrecan and type II collagen resistant to aggrecanases, collagenases, or both families of enzymes, to identify the most important proteolytic driver for cartilage erosion. Specifically, the cleavage site in the aggrecan interglobular domain (IGD) of Jaffa is changed from E<sup>373–374</sup>ALG to E<sup>373–374</sup>NVY and the collagenase cleavage site in the α1(II) chain of Bailey is changed from PQG<sup>775–776</sup>LAG to PPG<sup>775–776</sup>MPG. The Jaffa mutation does not influence aggrecanase cleavage at sites in the chondroitin sulphate-rich region of aggrecan. In contrast, blocking cleavage at the primary collagenase cleavage site prevents secondary and subsequent cleavage events in Bailey type II collagen. Juniper mice are resistant to both aggrecanases and collagenases Aggrecan loss from explants treated with IL-1α was significantly reduced in all mutant genotypes compared with Wildtype. The hierarchy of aggrecan loss was Wildtype &gt; Jaffa &gt; Bailey &gt; Juniper samples. Aggrecan loss from explants treated with retinoic acid was also significantly reduced in all mutant genotypes compared with wildtype. However, with retinoic acid treatment, the hierarchy of aggrecan loss was Wildtype &gt; Bailey &gt; Jaffa &gt; Juniper samples. We measured aggrecan loss and cartilage erosion 8-weeks after DMM surgery and found that both aggrecan loss and tibial cartilage erosion were significantly reduced in Juniper compared with Wildtype. Juniper was better protected against cartilage erosion than either Jaffa or Bailey In conclusion, mutations that partially block collagenolysis (heterozygous Bailey) and aggrecanolysis (homozygous Jaffa for the IGD site only) protect against cartilage erosion in experimental OA. Furthermore, protecting collagen II against collagenase attack is equal to, or better than, protecting aggrecan against IGD aggrecanase cleavage, in terms of cartilage erosion and aggrecan loss respectively. <h3>Disclosure of Interest</h3> None Declared
Paraneoplastic Hyperaldosteronism Associated with Non-Hodgkin's Lymphoma
Authors: Paolo Mulatero, Franco Rabbia, Franco Veglio
Journal: New England Journal of Medicine (2001)

To the Editor: Hyperaldosteronism is the cause of about 0.5 to 2 percent of all cases of hypertension. Aldosterone-producing adenomas account for approximately 60 percent of the cases of hyperaldos...
Abstract 524: Interaction of metastatic breast cancer cells with osteoblasts and osteoclasts in a 3D <i>in-vitro</i> model
Authors: Venkatesh Krishnan, Erwin A. Vogler, Andrea M. Mastro
Journal: Cancer Research (2010)

Abstract Breast cancer frequently metastasizes to bone where it causes osteolytic lesions. Although, the bone osteoclasts, not the cancer cells themselves, appear to be responsible for the bone resorbtion, we have evidence from 3D in vitro cell culture studies (bioreactor) that in the presence of breast cancer cells or their medium, the osteoblasts no longer make the proteins required for bone repair. Furthermore, they produce inflammatory cytokines, which in turn can stimulate osteoclasts. We have developed a bioreactor system that permits continuous growth of bone-accreting osteoblasts (MC3T3-E1) for &amp;gt; 10 months without subculture or perfusion. This results in a mineralizing, multiple-cell-layer tissue that strongly resembles normal bone. We have also shown that, by challenging this osteoblast tissue with human metastatic breast cancer cells (MDA-MB-231GFP), important hallmarks of cancer metastasis including single cell filing of cancer cells, cancer-cell penetration of tissue and colonization can be observed. We hypothesize that addition of osteoclast to this 3D mineralizing osteoblast in the bioreactor would be a relevant in vitro bone surrogate for studying stages of breast-cancer metastasis. In standard tissue culture and in the bioreactor, we have been able to differentiate osteoclasts from hematopoietic progenitor cells isolated from murine bone marrow. The osteoclasts formed by exposure to RANKL and M-CSF were multi-nucleated, TRAP positive cells. The pre-osteoclast cells when introduced onto the osteoblast grown in the bioreactor, differentiated to form multinucleated resorbing osteoclast, also positive for TRAP and actin ring staining. To further improve the bone remodeling aspect, pre-osteoblasts will be re-infused into the system and allowed to ‘re-mineralize’ the matrix resorbed by osteoclasts. Once the system is established, breast cancer cells will be added to examine the three way cell interactions. This 3D in-vitro cell culture system containing both osteoblast and osteoclast will help to further understand the cellular and molecular events that lead to successful breast cancer colonization of bone. Positive outcomes of the work will help clarify the etiology of metastasis but also create a much-needed in vitro tool for study of cancer therapeutics. This work was supported by US Army Medical and Materiel Command Breast Cancer Idea Program (W81XWH-06-1-0432). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 524.
Molecular characterization of breast cancer brain metastases and circulating tumor cells
Authors: H. Wikman, I. Hohensee, C. Riebensahm, I. Witzel, J. Matschke, M. Glatzel, K. Lamszus, S. Riehtdorf, V. Müller, K. Pantel
Journal: Annals of Oncology (2015)